Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PET/CT with ⁸⁹Zr-Df-IAB22M2C in Solid Tumors and Lymphoma
NCT03107663Phase 1Completed
- Sponsor
- ImaginAb
- Start
- Jun 2017
- Primary completion
- Aug 2018
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium-89 crefmirlimab berdoxam in solid tumor and Hodgkin lymphoma (HL), sponsored by ImaginAb. Primary endpoint: Safety and tolerability of ⁸⁹Zr-Df-IAB22M2C at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
solid tumorHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03107663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107663.